All Ireland Cancer Network (AllCaN) researchers are already making significant strides in preventing oesophageal cancer, particularly focusing on patients with Barrett’s oesophagus, a condition that can develop from chronic acid reflux and potentially lead to cancer. At the forefront of this research is Trinity College Dublin Professor of Translational Oncology and AllCaN Leader, Prof. Jacintha O’Sullivan and PhD Candidate Ms. Lorraine Smith. Funded by Breakthrough Cancer Research, this research is exploring innovative treatments utilising Mirai Medical’s electroporation technology, a technique involving electrical pulses to selectively target and treat abnormal cells while preserving surrounding healthy tissues. This method shows promise in reducing inflammation and preventing the progression from Barrett’s oesophagus to oesophageal cancer. Professor O’Sullivan’s work is crucial in understanding the mechanisms by which Barrett’s oesophagus evolves into cancer and in developing early intervention strategies. Electroporation, specifically, offers a non-invasive treatment option that could significantly alter the current approach to managing this precancerous condition. The potential of this technology lies in its ability to precisely target abnormal cells, thereby minimizing the risk of progression to cancer without the need for extensive surgical procedures. Breakthrough Cancer Research has notably highlighted the collaborative efforts in this field, noting the significant impact such technological advancements could have on patient outcomes. The goal is not only to treat Barrett’s oesophagus effectively but also to prevent the onset of oesophageal cancer, which remains one of the most challenging cancers to detect and treat in its early stages. This research represents a critical step forward in cancer prevention, combining cutting-edge technology with a deep understanding of the disease’s progression. To read more on this news, visit the Breakthrough Cancer Research and Independent website articles below.
